Home › Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
 

Keywords :   


Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%

2015-10-19 16:04:07| Biotech - Topix.net

The consensus forecast for Q3 revenue is at $7.81 billion, which is below the $8.24 billion reported in the previous quarter. The slight decline in revenue is due to a slowdown in the U.S. Hep C sales.

Tags: upcoming earnings digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »